The relative orientation of the TM3 and TM4 domains varies between α1 and α3 glycine receptors by Han, Lu et al.
 1 
The relative orientation of the TM3 and TM4 domains varies between α1  and 
α3  glycine receptors  
 
Han Lu1, Sahil Talwar1, and Joseph W. Lynch1,2 * 
 
1 Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia  
2 School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia 
*Corresponding author: Email: j.lynch@uq.edu.au  
 
 
ABSTRACT 
Glycine receptors (GlyRs) are anion-conducting members of the pentameric ligand-gated ion 
channel family. We previously showed that the dramatic difference in glycine efficacies of α1 and 
α3 GlyRs is largely attributable to their non-conserved TM4 domains. Because mutation of 
individual non-conserved TM4 residues had little effect, we concluded that the efficacy difference 
was a distributed effect of all non-conserved TM4 residues. We therefore hypothesized that the 
TM4 domains of α1 and α3 GlyRs differ in structure, membrane orientation and/or molecular 
dynamic properties. Here we employed voltage-clamp fluorometry to test whether their TM4 
domains interact differently with their respective TM3 domains. We found a rhodamine fluorophore 
covalently attached to a homologous TM4 residue in each receptor interacts differentially with a 
conserved TM3 residue. We conclude that the α1 and α3 GlyR TM4 domains are orientated 
differently relative to their TM3 domains. This may underlie their differential ability to influence 
glycine efficacy. 
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INTRODUCTION 
   Pentameric ligand-gated ion channels (pLGICs) are a family of membrane proteins that mediate 
fast neurotransmission in the brain. Functional pLGICs comprise five homologous subunits 
arranged symmetrically around a central pore. The extracellular N-terminal domain is comprised of 
eleven β-strands organized into a β-sheet sandwich with neurotransmitter-binding sites located at 
subunit interfaces. The transmembrane (TM) domain is comprised of four membrane-spanning α-
helices, termed TM1-TM4. A TM2 domain contributed by each of the five subunits lines the central 
pore. The TM2 domains are surrounded by the TM1, TM3 and TM4 domains that together provide 
a barrier between the hydrophilic pore and the hydrophobic membrane. The TM4 domain is largely 
surrounded by lipid and forms contacts with both TM1 and TM3. The TM4 extends beyond the 
other TM helices into the extracellular solution with its α-helical structure being maintained until 
the C-terminus.1  
   The glycine receptor (GlyR) is an anion-permeable pLGIC that mediates inhibitory 
neurotransmission in the spinal cord, retina and brainstem.2 A total of five GlyR subunits 
(α1−α4, β) are known and most synaptic GlyRs comprise α1β heteromers. Although the 
distribution of α3 subunits is generally limited, α3-containing GlyRs are highly expressed in 
inhibitory synapses on spinal nociceptive neurons.3 The α3 GlyR has thus emerged as a therapeutic 
target for analgesia, and indeed, drugs that specifically enhance α3 GlyR currents are effective in 
treating inflammatory and neuropathic pain.4 Because residues lining the neurotransmitter-binding 
sites of the α1 and α3 GlyRs are highly conserved, it seems unlikely that this binding-site could be 
successfully targeted by subunit-specific modulators. It is therefore important to identify alternate 
drug-binding sites that may exhibit a greater structural diversity between these GlyR isoforms. One 
possible site, known as the intra-subunit alcohol-binding site, is formed by the outer regions of all 
four TM α-helices.5 
   Glycine exhibits a much higher efficacy for the α1 GlyR than for the α3 GlyR.6 We recently 
employed a chimeric approach to show that their structurally divergent TM4 domains are 
responsible for a large part of this efficacy difference.6 Because mutation of individual non-
conserved TM4 residues had little effect on glycine efficacy, we concluded that the efficacy 
difference could not be attributed to specific molecular interactions but was more likely a 
distributed effect of all non-conserved TM4 residues. This prompted us to speculate that the TM4 
domains of the α1 and α3 GlyRs must differ either in their secondary structures, membrane 
orientation and/or molecular dynamic properties in either the closed and/or glycine-activated states. 
If so, then the intra-subunit alcohol binding site, to which the TM4 domain contributes, might be 
promising to investigate as a potential site for α3-specific modulators.  
   Here, we employed voltage-clamp fluorometry (VCF) to test the hypothesis that the TM4 
domains of the α1 and α3 GlyRs interact differently relative to their respective TM3 domains in the 
closed and/or open states.  
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RESULTS AND DISCUSSION 
   Relative to the α1 GlyR, the α3 GlyR contains two extra residues at the C-terminus (Figure 1A). 
Throughout the remainder of their TM4 domains, they share a 22/31 (= 71%) sequence identity and 
a 29/31 (= 94%) sequence homology. Full length homology structures of the α1 and α3 GlyRs were 
constructed using the C. elegans α1 glutamate-gated chloride channel (GluClR) crystal structure as 
a template.1 The sequence alignment used to generate these models is shown in Figure S1 
(Supporting information). The predicted structure of the α1 GlyR TM4 is shown in Figure 1A. The 
backbone structure of the α3 GlyR TM4 domain was almost identical, and in our full length 
receptor structures the respective domains subtended a common angle relative to the remainder of 
the protein. A significant difference, however, was that the α3 TM4 domain was rotated around its 
long axis by around 30o relative to the α1 GlyR TM4 domain. This is illustrated in Figure 1B and C 
by showing the α1 R414 sidechain in blue and the corresponding α3 R422 sidechain in orange. In 
Figure 1C, we chose an Arg rotamer that maximized the angular difference. The relative positioning 
of TM3 and TM4 residues along their helical axes in our α1 GlyR model is supported by an 
electrophysiological study that provided evidence for a disulfide bond between A288C and Y410C 
in the α1 GlyR.7 
   We employed VCF to investigate whether the TM4 domains of α1 and α3 GlyRs are oriented 
differentially relative to their TM3 domains in the closed and/or open states. VCF reports changes 
in the quantum efficiency of rhodamine derivatives that occur in response to changes in the polarity 
of their microenvironment.8,9 VCF involves introducing a cysteine into an otherwise cysteine-less 
receptor and covalently linking a thiosulfonate-tagged fluorophore to this introduced cysteine via a 
disulfide bond. By simultaneously recording current and fluorescence (ΔI and ΔF) responses, 
openings of the channel gate can be temporally correlated with conformational changes occurring in 
or around the labeled domain of interest. 
   As a first step, we individually mutated to cysteine all α1 GlyR TM4 residues from I409 – Q421, 
inclusive. After functionally expressing each mutant GlyR in Xenopus oocytes, we attempted to 
label each introduced cysteine in turn with MTSR and MTS-TAMRA (see Methods). The α1-I409C 
and α1-I410C GlyRs were not productively labelled by either compound and the α1-K411C GlyR 
was labelled by MTSR only (see below). The other 10 residues (α1-I412C – α1-Q421C) were all 
productively labeled by both MTS-TAMRA and MTSR, although MTS-TAMRA was used for 
further experiments as it yielded a dramatically larger maximal fluorescence response (ΔFmax) at 
each labelled site. Given that disulfide bond formation between thiosulfonates and sulfhydryl 
groups requires a polar environment 10, we inferred that the reactive residues face an aqueous 
environment. The locations of the 11 cysteine-substituted residues investigated in this study are 
shown in blue in Figure 1A.  
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   Glycine dose-response relationships were quantitated for each cysteine mutant GlyR prior to 
labelling, with all averaged ΔI glycine EC50, Hill coefficient (nH) and ΔImax values presented in 
Table 1. This analysis was repeated after covalent modification by either MTSR (α1-K411C) or 
MTS-TAMRA (α1-I412C – α1-R421C), with the averaged ΔI glycine EC50, nH and ΔImax values 
also presented in Table 1. All labelled mutants produced detectable ΔFs in response to glycine 
activation. Sample ΔI and ΔF dose-response relationships recorded from MTS-TAMRA-labelled 
α1-V413C, α1-R414C, α1-R415C and α1-E416C GlyRs are shown in Figure 2A-D together with 
their averaged ΔI and ΔF concentration-response relationships. The averaged ΔF glycine EC50, nH 
and ΔFmax values for these and all other tested α1 GlyR mutants are summarized in Table 1.  
   Figure S2 (Supplementary information) graphically illustrates several salient features of these 
results. The ΔImax values (Figure S2A) and the ΔI and ΔF glycine EC50 values (Figure S2B) did not 
vary significantly for any tested mutant relative to any other mutant using one-way ANOVAs and 
either Bonferroni or Dunnetts post hoc tests. Moreover, pairwise comparisons of the same 
parameters relative to the corresponding unmutated GlyR values using an unpaired t-test revealed a 
similar result (Table 1). These results imply that mutagenesis and labelling did not significantly 
impair the function of any of the constructs investigated here. Figure S2B also shows that most of 
the mutants exhibited ΔF EC50 values that were around an order of magnitude higher than the 
corresponding ΔI EC50 values. The sole exception to this was the α1-R414C GlyR where the 
respective EC50 values were much closer in value (Figure S2B). Two points are worthy of note 
concerning the mean ΔFmax values as summarized in Figure S2C. First, the MTSR labelled α1-
K411C GlyR exhibited an ΔFmax that was too small to permit quantitation of its glycine EC50 value. 
Second, the MTS-TAMRA labelled α1-R414C GlyR exhibited a ΔFmax that was opposite in sign to 
those of all the other tested mutants (see also Figure 2B). From all these results, we infer that the 
microenvironment of the label attached to the α1-R414C GlyR differs from that of the labels 
attached to the other residues. We thus hypothesize that the label attached to α1-R414C exhibits a 
glycine-dependent interaction with another chemical group. 
   Our α1 GlyR model predicts that R414 faces towards W286 in TM3 (Figure 1B). We therefore 
hypothesized that the rhodamine derivative attached to R414C interacts with W286 in a glycine-
dependent manner. As our model of the α3 GlyR predicts that α3-R422 (which corresponds to α1-
R414) is orientated differently relative to W286 (Figure 1C), we predict that the rhodamine 
derivative attached to α3-R422 exhibits a differential interaction with W286. To test these 
predictions, we investigated the effects of the W286F mutation on the glycine-induced ΔF 
responses of rhodamine derivatives attached individually to V413C, R414C, R415C or E416C in 
the α1 GlyR and L421C, R422C, H423C or E424C in the α3 GlyR. 
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   Glycine dose-response relationships were quantitated for the double mutant α1-W286F-V413C 
GlyR, α1-W286F-R414C GlyR, α1-W286F-R415C GlyR and α1-W286F-E416C GlyRs before and 
after labeling with MTS-TAMRA, with all averaged ΔI glycine EC50, nH and ΔImax values presented 
in Table 1. The W286F mutation dramatically increased the glycine EC50 values of all four 
constructs, although MTS-TAMRA labeling tended to reverse this trend. The W286F mutation also 
produced a dramatic, uniform reduction in the ΔFmax values of all four labeled double mutant α1 
GlyRs (Figure 3A, B). However, the sign of glycine-induced ΔFmax was not changed in the α1-
W286F-V413C GlyR, the α1-W286F-R415C GlyR and the α1-W286F-E416C GlyR. Together 
these results imply a non-specific, indirect effect of W286F on receptor gating efficacy and on the 
propensity of labels attached to TM4 residues to experience an altered microenvironment between 
the unliganded and glycine-activated states. However, in contrast to these results, the sign of the 
glycine-induced ΔFmax at the labeled α1-W286F-R414C GlyR was reversed relative to the α1-
R414C GlyR (Table 1, Figure 3B). This indicates that the glycine-induced microenvironmental 
change at the label attached to this R414C was altered by W286F. This in turn provides strong 
support for a specific interaction between W286 and the label attached to R414C, as predicted by 
our model. 
   A similar experimental approach was applied to the α3 GlyR. Glycine dose-response relationships 
were quantitated for the single mutant α3-L421C, α3-R422C, α3-H423C and α3-E424C GlyRs 
both before and after labeling with MTS-TAMRA, and all averaged ΔI glycine EC50, nH and ΔImax 
values are presented in Table 2. As with the corresponding α1 GlyR mutations, these mutations had 
little effect on ΔImax or glycine EC50 values. Surprisingly, glycine-induced ΔFmax responses were 
invariably much smaller than those observed at the corresponding α1 GlyR mutants, and for this 
reason the ΔF glycine EC50 values could not be quantitated (Table 2, Figure 3C). Introduction of the 
W286F mutation produced a dramatic increase in ΔI glycine EC50 without significantly affecting the 
ΔImax values (Table 2, Figure 3D). MTS-TAMRA labeling significantly reduced the ΔI glycine EC50 
values at all four mutant receptors (Table 2). All of these effects were similar to those observed at 
the α1 GlyR, implying a non-specific effect of the W286F mutation on the gating efficacy of both 
GlyRs. However, for all four double mutant α3 GlyRs, neither the sign nor the magnitude of 
glycine-induced ΔFmax was altered by the W286F mutation (Table 2, Figure 3D). We thus infer that 
the label attached to R422C in the α3 GlyR exhibits a different interaction with W286F than the 
one attached to R414C in the α1 GlyR. This provides strong evidence for a differential orientation 
of the α1 and α3 TM4 domains relative to their TM3 domains during glycine-activation. 
   There is currently little information as to how TM4 domains contribute to channel activation. In 
the muscle nicotinic receptor, the TM4 domain moves as a unit approximately midway through the 
gating reaction.11 Molecular dynamics simulations concur with the idea of TM4 moving as a rigid 
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α-helix, but with relatively small amplitude movements.12 Electrophysiological studies on a variety 
of pLGICs have shown that mutations to TM4 residues strongly influence gating efficacy in a 
manner that suggests altered interactions with the surrounding lipid environment.6,13-16 Indeed, 
biochemical investigations have shown that TM4 orientation and movement is altered by the lipid 
environment17 and that this in turn can potently modulate channel gating efficacy.18 However, there 
is as yet no information as to whether structurally conserved TM4 domains in homologous pLGIC 
subunits may be oriented differently with respect to the remainder of the protein. This is the issue 
that the present study sought to address. 
   Before interpreting our data, it is necessary to consider the limitations of VCF for interpreting 
conformational changes in ligand-gated ion channels. Briefly, a ligand-induced ΔF implies that the 
microenvironment of an attached fluorophore has been altered via a direct fluorophore-ligand 
interaction, a ligand-induced conformational change associated with channel opening and/or a 
ligand-induced conformational change associated with a mechanism (e.g., desensitization) unrelated 
to channel opening. Although we can eliminate direct fluorophore-ligand interactions on the 
grounds that TM4 is distant from the glycine-binding site, we cannot discriminate between the other 
two possibilities. However, as the ΔF EC50 was an order of magnitude higher than the ΔI EC50 at 
most mutants (Figure S2B, Supplementary information), we infer that the movements we detected 
in TM4 reflect either high levels of binding site occupancy or entry into a desensitized state. In 
either case, it is possible that the movements reported here may not essential to weakly activate the 
channels.  
   In the α1 GlyR, labels attached to 10 of the 11 TM4 sites responded to glycine in a remarkably 
similar manner, with negative ΔFs and large offsets between ΔI and ΔF glycine EC50s (Figure S2B). 
It is not easy to explain the uniformity of these responses. We infer these ΔFs occurred in response 
to a generically altered lipid/water environment. The alternative possibility, that the ΔFs were due 
to state-dependent differences in molecular interactions with neighbouring receptor domains, is 
unlikely given that all ΔFs varied in the same direction. For example, in this scenario labels 
attached to sites facing away from TM3 should have produced no ΔF at all. The sole exception to 
this rule was the response of the label attached to R414C. The reversed hydrophobicity change at 
this site implies a different chemical origin from those that occurred at the other labeled sites. The 
similarity of the ΔI and ΔF glycine EC50 values implies the label may have sensed a conformational 
change in the TM3 that was associated with activation. Mutagenesis of W286 confirmed this 
interaction.  
   In contrast, W286F did not affect the sign or magnitude of the ΔF at the labeled R422C mutant α3 
GlyR. Thus, labels attached to homologous residues in α1 and α3 GlyRs do not sense the same 
microenvironmental change during activation. This strongly suggests that the respective TM4 
domains exhibit different secondary structures, membrane orientations or molecular dynamic 
properties in either the closed and/or glycine-activated states. As our molecular modeling predicts 
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that the respective TM4 domains have modestly different orientations relative to TM3, it provides 
support for this conclusion. However, as our models are based on a crystal structure, they may not 
accurately reflect the orientations of the TM4 domains under physiological lipid conditions. It is 
also important to consider that we excised the large intracellular TM3-4 domains to generate our 
models. As these domains differ in length between α1 and α3 GlyRs, their presence may influence 
TM4 orientation and molecular dynamic properties. Thus, we consider the models may not be 
sufficiently precise to accurately interpret our results.  
   In summary, we conclude that the TM4 domains of the α1 and α3 GlyRs differ either in their 
secondary structures, membrane orientations or molecular dynamic properties in either the closed 
and/or glycine-activated states. This may explain their capacity to differentially influence glycine 
efficacy. It also suggests that the intra-subunit alcohol binding site to which each TM4 domain 
contributes might be promising to investigate as a potential binding site for α3-specific modulators.  
 
METHODS 
Molecular Biology. Plasmid DNAs for the human α1 and rat α3 GlyR subunits were each 
subcloned into the pGEMHE vector. All constructs employed in this study were made on the C41A 
background to eliminate the only uncrosslinked extracelular cysteine. QuickChange (Stratagene, La 
Jolla, CA) was used to generate all mutants used in this study. Automated sequencing of the entire 
coding sequence was used to confirm the successful incorporation of mutations. Capped mRNA for 
oocyte injection was generated using mMessage mMachine (Ambion, Austin, TX).  
Oocyte Preparation, Injection and Labeling. Oocytes from female Xenopus laevis (Xenopus 
Express, France) were prepared as previously described 19 and injected with 10 ng of mRNA. The 
oocytes were then incubated at 18 °C for 3-5 days in ND96 solution containing 96 mM NaCl, 2 mM 
KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 0.6 mM theophylline, 2.5 mM pyruvic acid, 50 
µg/ml gentamycin, pH 7.4.  
Fluorophore labeling. Rhodamine methanethiosulfonate (MTSR) and 2-((5(6)-
tetramethylrhodamine) carboxylamino)ethyl methanethiosulfonate (MTS-TAMRA), both from 
Toronto Research Chemicals (North York, ON), were dissolved in dimethyl sulfoxide and stored at 
-20°C. On the day of recording, oocytes were incubated for 30 s in 10 µM MTSR or MTS-TAMRA 
dissolved in ice-cold ND96. Oocytes were then thoroughly washed and stored in ND96 for up to 6 
hr on ice before recording. As unmutated α1 and α3 GlyRs never exhibited a glycine-induced 
fluorescence change (ΔF) or a change in electrophysiological properties following fluorophore 
incubation19 (Table 1), we can rule out non-specific labeling.  
VCF and Data Analysis. Oocytes were placed in a recording chamber on an inverted microscope.20 
The microscope was equipped with a high-Q tetramethylrhodamine isothiocyanate filter set 
(Chroma Technology, Rockingham, VT), a Plan Fluor 40x objective lens (Nikon Instruments, 
Kawasaki, Japan), and a Hamamatsu H7360-03 photomultiplier (Hamamatsu Photonics, 
Hamamatsu City, Japan) coupled to a PMT400R Photomultiplier sub-system (Ionoptix, Milton, 
MA). A 150 W halogen lamp was used as light source. Cells were maintained at -40 mV by 
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conventional two-electrode voltage-clamp and currents were recorded with a Gene Clamp 500B 
amplifier (Axon Instruments, Union City, CA). Current and fluorescence traces were acquired at 
200 Hz via a Digidata 1322A interface using Clampex 9.2 software (Axon Instruments, Union City, 
CA). For analysis and display, fluorescence signals were digitally filtered at 1-2 Hz with an eight-
pole Bessel filter. Results are expressed as mean ± SEM of three or more independent experiments. 
The Hill equation was used to calculate the EC50 and nH values for glycine activation. All curves 
were fitted using a non-linear least squares algorithm (Sigmaplot 9.0, Jandel Scientific, San Rafael, 
CA, USA). 
Molecular Modeling. Full length human α1 and rat α3 GlyR structures were modeled on the C. 
elegans α GluClR crystal structure (PDB code: 3RIF).1 The alignment between GluClR and the 
GlyR subunits was optimized using CLUSTAL W. Based on alignment, the GlyR sequences were 
edited to excise the large intracellular TM3-4 domain. Modeller v9.10 was then used to generate the 
tertiary structure models. The variable target function method was used initially to generate 50 
randomized models.21 The quality of these models were compared in terms of various statistically 
derived structure quality assessment scales that included Ramachandran Plot, Errat Score, Z-Score 
and initial packing quality.22-24 Structures with the highest Z-scores were selected for energy 
minimisations using Gromacs. Unfavourable contacts in each structure were relieved by two cycles 
(5000 steps each) of steepest distance and conjugate gradient minimisations.25 To further validate 
the structure, the standard ligands glycine and strychnine were docked using FlexX.26 The pose 
output limit was set to 20 for each run for extensive conformational sampling. For both the α1 and 
α3 GlyRs, the docked orientations were found to be identical to the binding orientations as shown 
in previous studies.27,28 
 
  
 9 
AUTHOR INFORMATION 
Corresponding author 
* Telephone: (+617) 33466375. Fax: (+617) 33466301. 
Author contributions 
Participated in research design: H.L. and J.W.L.  
Conducted experiments and performed data analysis: H.L. and S.T. 
Wrote manuscript: H.L., S.T. and J.W.L. 
Funding 
Funding for this research was received from the Australian Research Council and the National 
Health and Medical Research Council of Australia. 
Notes 
The authors declare no competing financial interest.  
 
SUPPORTING INFORMATION AVAILABLE 
This contains additional figures as described in the text. This information is available free of charge 
via the Internet at http://pubs.acs.org/. 
 
ABBREVIATIONS 
ΔF, change in fluorescence; ΔFmax, maximum change in fluorescence; ΔI, change in current; ΔImax, 
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FIGURE LEGENDS 
 
Figure 1. Comparison of TM4 domains in α1 and α3 GlyRs. A. Sequence alignment of TM4 
domains and C-terminal tails, together with a homology model of the α1 TM4 domain. Residues 
investigated in this study are coloured blue in the model and in the primary sequence. B. Structural 
model of the outer TM region of the α1 GlyR, viewed from within the membrane, with the W286 
and R414 sidechains coloured red and blue, respectively. Lower panel shows a view from the 
synapse with extracellular domain removed. B. Corresponding views of the α3 GlyR structure, with 
the W286 and R422 sidechains coloured red and orange, respectively. The position of R422 in the 
α3 primary sequence is shown in orange in A.  
 
Figure 2. Sample ΔI and ΔF recordings and their averaged dose-response relationships from MTS-
TAMRA-labeled α1-V413C GlyRs (A), α1-R414C GlyRs (B), α1-R415C GlyRs (C) and α1-
E416C GlyRs (D). In this and subsequent figures, glycine-induced ΔI and ΔI responses are shown 
in black and red, respectively, and glycine applications are indicated by black bars. Mean ΔI and ΔF 
glycine EC50, nH, ΔImax and ΔFmax values of best fit to individual dose-response relations are 
presented in Table 1.  
 
Figure 3. Effect of the W286F mutation on the functional properties of MTS-TAMRA-labeled 
mutant α1 and α3 GlyRs. A. Examples of ΔImax and ΔFmax responses induced by saturating glycine 
in the indicated single mutant α1 GlyRs. The four traces are reproduced from Figure 2. B. 
Examples of ΔImax and ΔFmax responses induced by saturating glycine in double mutant α1 GlyRs. C. 
Examples of ΔImax and ΔFmax responses induced by saturating glycine in the corresponding single 
mutant α3 GlyRs. D. Examples of ΔImax and ΔFmax responses induced by saturating glycine in the 
corresponding double mutant α3 GlyRs. All averaged values are given in Tables 1 and 2.  
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Table 1. Properties of agonist-activated ΔI and ΔF responses at mutant α1  GlyRs. 
 
Electrophysiological and fluorescence data are shown in normal and bold type, respectively. 
  
Construct EC50  (µM) nH 
ΔImax 
(µA) ΔFmax (%) n 
α1-WT unlabeled ΔI 17.9 ± 1.5 2.8 ± 0.1 4.8 ± 0.4 - 4 
α1-WT labeled ΔI 17.1 ± 0.6 2.8 ± 0.2 4.9 ± 0.7 - 4 
α1-WT labeled ΔF - - - - 4 
α1-K411C unlabeled ΔI 45 ± 3aaa 3.2 ± 0.5 4.5 ± 0.8 - 4 
α1-K411C labeled ΔI 88 ± 6bb 2.3 ± 0.3 b 3.3 ± 0.5 - 4 
α1-K411C labeled ΔF - - - -1.4 ± 0.2 4 
α1-I412C unlabeled ΔI 17.4 ± 3.7 2.0 ± 0.3 4.7 ± 0.4 - 4 
α1-I412C labeled ΔI 7.7 ± 0.6b 1.9 ± 0.4 2.2 ± 0.3 - 5 
α1-I412C labeled ΔF 153 ± 4 ccc 1.0 ± 0.1 - -5.3 ± 0.5 5 
α1-V413C unlabeled ΔI 26.6 ± 4.8 1.9 ± 0.4 4.3 ± 0.4 - 5 
α1-V413C labeled ΔI 8.4 ± 0.7 bb 2.1 ± 0.2 2.5 ± 0.1 - 6 
α1-V413C labeled ΔF 262 ± 44ccc 2.1 ± 0.3 - -27.0 ± 1.8 6 
α1-R414C unlabeled ΔI 24.3 ± 1.1a 2.9 ± 0.1 2.4 ± 0.3 - 4 
α1-R414C labeled ΔI 20.5 ± 2.9 2.6 ± 0.4 2.3 ± 0.3 - 6 
α1-R414C labeled ΔF 41 ± 7c 1.5 ± 0.1c - +3.1 ± 0.4 6 
α1-R415C unlabeled ΔI 11.5 ± 1.4a 2.7 ± 0.3 3.1 ± 0.3 - 5 
α1-R415C labeled ΔI 11.2 ± 0.6 2.6 ± 0.2 2.5 ± 0.2 - 6 
α1-R415C labeled ΔF 277 ± 23 ccc 1.5 ± 0.1cc - -17.6 ± 1.6 6 
α1-E416C unlabeled ΔI 8.0 ± 1.0 aa 2.9 ± 0.1 2.7 ± 0.1 - 5 
α1-E416C labeled ΔI 8.0 ± 0.8 2.3 ± 0.3  2.6 ± 0.2 - 5 
α1-E416C labeled ΔF 369 ± 28 ccc 1.1 ± 0.2 c - -7.9 ± 1.7 5 
α1-D417C unlabeled ΔI 10.1 ± 0.2a 3.1 ± 0.2 3.1 ± 0.3 - 3 
α1-D417C labeled ΔI 8.6 ± 0.4  2.3 ± 0.2 2.6 ± 0.1 - 5 
α1-D417C labeled ΔF 217 ± 19 ccc 2.1 ± 0.2c - -11.3 ± 1.2 5 
α1-V418C unlabeled ΔI 13.3 ± 0.9 3.6 ± 0.7 3.2 ± 0.7 - 4 
α1-V418C labeled ΔI 6.7 ± 0.8 b 2.2 ± 0.2b 2.7 ± 0.1 - 5 
α1-V418C labeled ΔF 318 ± 35cc 1.1 ± 0.1c - -6.9 ± 0.3 5 
α1-Η419C unlabeled ΔI 13.7 ± 1.3 3.6 ± 0.2 2.9 ± 0.2 - 4 
α1-Η419C labeled ΔI 14.9 ± 1.6 3.1 ± 0.2  2.7 ± 0.2 - 5 
α1-Η419C labeled ΔF 311 ± 21ccc 1.4 ± 0.1cc - -9.3 ± 1.9 5 
α1-Ν420C unlabeled ΔI 14.5 ± 0.8 3.3 ± 0.1 2.9 ± 0.2 - 5 
α1-Ν420C labeled ΔI 24.7 ± 4.4  2.1 ± 0.3bb 3.1 ± 0.1 - 6 
α1-Ν420C labeled ΔF 288 ± 22 ccc 1.9 ± 0.1 - -11.9 ± 1.1 6 
α1-Q421C unlabeled ΔI 14.8 ± 1.5 3.4 ± 0.6 3.5 ± 0.1 - 5 
α1-Q421C  labeled ΔI 26.7 ± 4.6  1.7 ± 0.3b 3.0 ± 0.2 - 5 
α1-Q421C labeled ΔF 329 ± 13ccc 1.8 ± 0.1 - -11.7 ± 0.8 5 
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a - significant difference to electrophysiological properties of unlabeled α1-WT GlyRs (unpaired 
Student’s t-test, a p<0.05, aa p<0.01, aaa p<0.001) 
b - significant difference to electrophysiological properties before labeling in the same mutant GlyR 
(unpaired Student’s t-test, b p<0.05, bb p<0.01, bbb p<0.001)  
c - significant difference of fluorescence properties to electrophysiological properties after labeling 
in the same mutant GlyR (paired Student’s t-test, c  p<0.05,cc p<0.01, ccc p<0.001) 
 
  
α1-W286F-V413C unlabeled ΔI 475 ± 14aaa 3.1 ± 0.2 5.7 ± 0.4 - 3 
α1-W286F-V413C labeled ΔI 190 ± 56bb 2.2 ± 0.1b 5.7 ± 0.3 - 4 
α1-W286F-V413C labeled ΔF - - - -2.5 ± 0.4 4 
α1-W286F-R414C unlabeled ΔI 792 ± 20aaa 3.0 ± 0.2 4.7 ± 0.4 - 5 
α1-W286F-R414C labeled ΔI 182 ± 34bbb 2.0 ± 0.2b 3.7 ± 0.4 - 5 
α1-W286F-R414C labeled ΔF - - - -1.8 ± 0.3 5 
α1-W286F-R415C unlabeled ΔI 602 ± 89aaa 3.2 ± 0.1 3.9 ± 0.4 - 3 
α1-W286F-R415C labeled ΔI 213 ± 67bbb 2.1 ± 0.1bb 3.8 ± 0.2 - 5 
α1-W286F-R415C labeled ΔF - - - -2.2 ± 1.2 5 
α1-W286F-E416C unlabeled ΔI 579 ± 69aaa 3.2 ± 0.4 3.3 ± 0.6 - 3 
α1-W286F-E416C labeled ΔI 199 ± 19bb 2.0 ± 0.2b 3.2 ± 0.2 - 4 
α1-W286F-E416C labeled ΔF - - - -1.8 ± 0.4 4 
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Table 2. Properties of agonist-activated ΔI and ΔF responses at mutant α3  GlyRs. 
 
Electrophysiological and fluorescence data are shown in normal and bold type, respectively. 
 
 
a - significant difference to electrophysiological properties of unlabeled α1-WT GlyRs (unpaired 
Student’s t-test, a p<0.05, aa p<0.01, aaa p<0.001) 
b - significant difference to electrophysiological properties before labeling in the same mutant GlyR 
(paired Student’s t-test, b p<0.05, bb p<0.01, bbb p<0.001)  
  
 
 
 
 
  
Construct EC50  (µM) nH Imax (µA) ΔFmax (%) n 
α3-WT unlabelled ΔI 74 ± 2 2.9 ± 0.2 5.4 ± 0.6 - 6 
α3-WT labeled ΔI 71 ± 2 2.9 ± 0.2 5.6 ± 0.5 - 6 
α3-WT labeled ΔF - - - - 6 
α3-L421C unlabeled ΔI 27.1 ± 0.3aaa 2.5 ± 0.1 4.1 ± 0.2 - 3 
α3-L421C labeled ΔI 31 ± 1 2.6 ± 0.2 4.6 ± 0.4 - 4 
α3-L421C labeled ΔF - - - -1.8 ± 0.1 4 
α3-R422C unlabeled ΔI 35 ± 2aaa 2.6 ± 0.3 3.7 ± 0.3 - 3 
α3-R422C labeled ΔI 23.9 ± 0.4  3.8 ± 0.2b 4.9 ± 0.6 - 5 
α3-R422C labeled ΔF - - - -1.2 ± 0.1 5 
α3-H423C unlabeled ΔI 36 ± 1aaa 3.0 ± 0.2 4.9 ± 0.3 - 3 
α3-H423C labeled ΔI 36 ± 2 3.6 ± 0.6 5.2 ± 0.4 - 4 
α3-H423C labeled ΔF - - - -0.9 ± 0.1 4 
α3-E424C unlabeled ΔI 52 ± 2aa 2.8 ± 0.1 4.3 ± 0.5 - 4 
α3-E424C labeled ΔI 28.2 ± 0.5b 2.8 ± 0.2 4.9 ± 0.7 - 5 
α3-E424C labeled ΔF - - - -0.9 ± 0.2 5 
α3-W286F-L421C unlabeled ΔI 898 ± 59aaa 3.0 ± 0.4 3.9 ± 0.3 - 3 
α3-W286F-L421C labeled ΔI 165 ± 36bbb 2.0 ± 0.3b 2.5 ± 0.5 - 3 
α3-W286F-L421C labeled ΔF - - - -2.1 ± 0.3 3 
α3-W286F-R422C unlabeled ΔI 934 ± 70aaa 3.3 ± 0.1 2.9 ± 0.2 - 3 
α3-W286F-R422C labeled ΔI 248 ± 44bbb 2.4 ± 0.4b 2.8 ± 0.3 - 4 
α3-W286F-R422C labeled ΔF - - - -1.3 ± 0.2 4 
α3-W286F-H423C unlabeled ΔI 742 ± 62aaa 3.4 ± 0.4 3.3 ± 0.3 - 3 
α3-W286F-H423C labeled ΔI 277 ± 65bb 1.8 ± 0.3bb 2.7 ± 0.2 - 5 
α3-W286F-H423C labeled ΔF - - - -1.5 ± 0.3 5 
α3-W286F-E424C unlabeled ΔI 798 ± 82aaa 3.0 ± 0.4 3.8 ± 0.5 - 3 
α3-W286F-E424C labeled ΔI 236 ± 35bbb 1.8 ± 0.3bb 2.8 ± 0.3 - 3 
α3-W286F-E424C labeled ΔF - - - -1.8 ± 0.4 3 
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Figure S1. Amino acid sequence alignment of the TM3 and TM4 domains of the 
human α1 GlyR, the human α3 GlyR and the C. elegans α GluClR that were used to 
generate the structural models of α1 GlyR and α3 GlyR from the C. elegans α 
GluClR crystal structure (PDB code: 3RIF).  
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Figure S2. Functional comparison of MTS-TAMRA-labeled α1 GlyRs. A. Mean 
ΔImax values for all labeled α1 GlyRs investigated here reveals no significant variation 
using ANOVA and post-hoc tests as described in the text. B. Mean ΔI EC50 and ΔF EC50 values (shown in black and red, respectively) differed by around an order of 
magnitude at all labeled sites except for R414C. C. Mean ΔFmax values were negative at all labeled sites except for R414C.  
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